Lupin Pharmaceuticals Inc. is recalling 2,724 bottles of clomiPRAMINE hydrochloride Capsules USP (25 mg), a prescription medication used to treat obsessive-compulsive disorder. This recall was initiated after a long-term stability study revealed that the medication was breaking down into an unspecified degradation product that exceeded safety specifications. The affected medication was distributed nationwide in 100-count bottles.
The presence of degradation products means the medication has begun to break down chemically, which can result in the drug being less effective or containing impurities that do not meet safety standards. Patients should consult their doctor to ensure their treatment remains effective.
You have 2 options:
Rx only; Manufactured For: Lupin Pharmaceuticals, Inc., Baltimore, MD; Manufactured By: Lupin Limited, Nagpur, India
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.